Направление
Препараты против старения
Клетки постоянно регулируют процессы роста, восстановления и переработки своих компонентов. Лекарства могут влиять на эту регуляцию. Исследователи проверяют новые молекулы и заново изучают существующие препараты, чтобы выяснить, действуют ли они на само старение.
Следующий вопрос
Какие полезные эффекты, обнаруженные у мышей, сохраняются у людей?
Данные исследованийЭксперимент на мышах
В исследовании 2009 года, проведённом в трёх центрах, мыши, начавшие получать рапамицин в пожилом возрасте, жили дольше. Эксперимент показал, что препарат, воздействующий на сигнальный путь механистической мишени рапамицина (mTOR), может увеличить продолжительность жизни даже при начале лечения в старости.
Что остаётся выяснить. Исследование проводили на мышах. Схема приёма, которая продлевала бы жизнь человека, по его результатам остаётся неустановленной.
Прочитать статьюRapamycin fed late in life extends lifespan in genetically heterogeneous miceHarrison et al. · Nature · 2009Сравнение
Сравнение проектов с оценками
| Проект▲ | Обещанный эффект▲ | Доказательства▲ | Стадия▲ | Самый весомый довод против▲ |
|---|---|---|---|---|
| Aptah Bio | +2 года жизни | The strongest evidence is a peer-reviewed Scientific Reports article with iPSC-derived AD neurons and SAMP8 mice, reporting molecular and electrophysiology changes but explicitly no cognitive change in mice. | Preclinical. | The failure case is that Aptah’s claimed breadth is mostly narrative, while the real effects are narrow, model-specific, or too small to translate. |
| Beijing Joekai Biotechnology | +0,7 года жизни | The evidence base is stronger than a pure concept because it includes Joekai-assigned Alzheimer’s patents, a 2025 conference/news report of discovery and preclinical results for 50561, and a completed Phase IIa randomized placebo-controlled trial listing with 68 participants across 12 Chinese sites. | Historically, Joekai held Alzheimer’s-treatment patent filings and grants tied to synthetic compounds, though several records show ceased or fee-related expiry risks. | The evidence base is still dominated by patents, directory entries, and conference/trial metadata without published outcomes, so the project could easily be a case where a plausible mechanism and real clinical activity never translate into meaningful efficacy, differentiation, or durable IP advantage. |
| NYC-Vita | +1,5 года жизни | The project has credible institutional and competition validation: Mount Sinai/NYC-Vita was named an XPRIZE Healthspan semifinalist and Milestone 1 awardee with funding for a New York City clinical trial. | Status is early and unproven. | NYC-Vita could fail because the intervention is a heterogeneous bundle with weak attribution, small sample size, and substantial forward-looking promotional framing; the most likely disappointing outcome is that exercise explains most of the effect, while rapamycin/lamivudine add safety risk, noise, or negligible incremental benefit without clear mechanistic readouts. |
| RIGHT Trial | +1,2 года жизни | The evidence base is thin for the actual frailty indication. | Clinical-stage and actively structured as a mid-stage efficacy/safety test, with University of Pittsburgh as lead sponsor, Anne B. | Frailty is biologically heterogeneous and may not respond meaningfully to single-cytokine suppression; even if IL-6 is associated with frailty, blocking it may produce limited functional benefit, unacceptable tradeoffs, or effects too small to justify chronic biologic treatment in older adults. |
| Team GlyNAC | +2 года жизни | There is more than pure preclinical speculation: evidence includes a randomized older-adult clinical trial, a pilot older-adult clinical trial, mouse lifespan and cognition studies, and smaller disease-context studies in type 2 diabetes and HIV. | Status is early clinical and preclinical, not validated. | The main failure case is that the project is over-extrapolating from small studies, institutional news coverage, and mouse data: biomarker improvements may not translate into durable clinical benefit, lifespan effects may be species-specific, sex-dependent responses may complicate generalization, and Baylor’s patent/licensing position creates conflict-of-interest pressure around interpretation. |
| Team Twilight | +1,2 года жизни | The evidence base supports the broader HERV-K/HML-2 ALS hypothesis better than it supports Team Twilight’s therapeutic program. | The project appears to be a venture-stage therapeutic company in a preclinical or at least not yet clinically validated state based on the evidence here. | The main failure case is that the project is still resting on promotional claims plus field-context biology that does not yet prove intervention efficacy. |
Компании
Компании этого направления
Заявленные цели отражают то, чего компания обещает достичь. Независимое воспроизведение результатов показывает, что подтвердили другие исследователи. Сопоставляйте обе колонки: разрыв между ними показывает, насколько обещания опережают подтверждённые результаты.
| Компания▲ | Масштаб цели▲ | Независимое воспроизведение▲ | Стадия▲ | Главный офис▲ |
|---|---|---|---|---|
| 5 Alarm Bio 5 Alarm Bio develops small-molecule therapeutics targeting an unexplored aging mechanism to delay or prevent age-related diseases. | 7 | 1 | seed | Cambridge, United Kingdom |
| 712 North Inc 712 North develops personalized mitochondrial medicines for age-related diseases. | 7 | 3 | – | San Francisco, California, United States |
| ADvantage Therapeutics ADvantage Therapeutics develops novel therapeutics for neurodegenerative conditions, with a major focus on Alzheimer’s disease. | 8 | 3 | – | Vienna, Austria |
| Aeovian Pharmaceuticals Clinical-stage biopharmaceutical company developing selective small molecules for rare genetic and age-related diseases. | 6 | 1 | – | 2930 Domingo Avenue #145, Berkeley, CA 94705 |
| AKL Therapeutics AKL Therapeutics develops APPA, an investigational oral therapy for osteoarthritis and other inflammatory diseases of ageing. | 6 | 4 | – | Stevenage, United Kingdom |
| Amplifier Therapeutics Amplifier Therapeutics develops AMPK activators to address metabolic disease and aging-related chronic diseases. | 6 | 2 | – | United States |
| Antoxis Antoxis conducted research and experimental development in biotechnology. | 4 | 2 | pre seed | Aberdeen, Scotland, United Kingdom |
| Atropos Therapeutics Atropos develops senescence-targeting drugs for aging-related diseases, cancer, and healthspan. | 7 | 3 | – | San Francisco, California, United States |
| Biophytis Biophytis develops transformative therapies impacting longevity, with BIO101 programs in sarcopenia and obesity. | 7 | 3 | public | Paris, France |
| Biosplice (was Samumed) Biosplice develops first-in-class therapies based on alternative splicing and small-molecule CLK/DYRK kinase inhibition. | 7 | 2 | – | San Diego, California, United States |
| Bolden Therapeutics Bolden Therapeutics develops first-in-class therapeutics to increase neurogenesis and improve outcomes in neurological disease. | 7 | 1 | pre seed | Boston, Massachusetts, United States |
| Cambrian Bio Clinical-stage drug development company developing therapeutics targeting metabolic pathways that decline with age. | 8 | 2 | series c plus | New York, New York |
| Cognition Therapeutics Cognition Therapeutics develops therapies for age-related neurodegenerative diseases including dementia with Lewy bodies and Alzheimer’s disease. | 7 | 3 | public | New York City, New York, United States; Pittsburgh, Pennsylvania, United States |
| Coya Therapeutics Clinical-stage biotechnology company developing multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases. | 8 | 4 | public | Houston, Texas, United States |
| Cytonics Cytonics develops A2M-based biologic treatments intended to halt or reverse osteoarthritis progression. | 5 | 2 | – | Jupiter, Florida, United States |
| Epirium Bio Epirium Bio develops oral small-molecule therapies targeting PGE-2 signaling for neuromuscular, inflammatory, and fibrotic diseases. | 7 | 4 | series a | United States |
| Etheros Pharmaceuticals Etheros develops small molecule enzyme mimetics for neuroprotection and healthspan. | 7 | 1 | – | United States |
| Fission Pharma Fission Pharma is developing DRP1-FIS1 protein-protein interaction inhibitors for chronic inflammation, mitochondrial dysfunction, and age-related degenerative diseases. | 7 | 1 | pre seed | United States |
| Fountain Therapeutics Fountain develops first-in-class therapies for diseases and conditions caused by aging. | 7 | 1 | – | San Francisco, California, United States |
| Galilei Biosciences Galilei Biosciences develops small-molecule SIRT6 activators for neuroprotection in glaucoma and other age-related diseases. | 7 | 5 | – | Cambridge, Massachusetts, United States |
| Hayflick Partners Hayflick Therapeutics develops localized, micro-dose rapamycin therapies targeting mTOR for cellular aging interventions in skin. | 6 | 3 | – | Narberth, Pennsylvania, United States |
| HCW Biologics Clinical-stage biopharmaceutical company developing fusion immunotherapies for autoimmune diseases, cancer and senescence-associated dysplasia. | 8 | 3 | public | Miami, Florida, United States |
| Immunis Clinical-stage biotech developing stem cell-derived secretome biologics targeting age-related muscle and metabolic disease. | 8 | 3 | – | Irvine, California |
| Istesso Istesso develops first-in-class oral regenerative medicines focused on restoring the body’s natural capacity to repair tissue. | 8 | 2 | – | London, United Kingdom |
| Jocasta Neuroscience Jocasta develops Klotho-based therapeutics for cognitive vitality and age-related cognitive impairment. | 8 | 4 | series a | – |
| Jupiter Neurosciences A clinical-stage drug platform company focused on treating neuroinflammation. | 6 | 2 | – | Palm Beach Gardens, Florida, United States |
| Juvenescence Juvenescence develops innovative medicines targeting core aging mechanisms to extend healthy lifespan and prevent age-related diseases. | 7 | 2 | – | – |
| LinkGevity LinkGevity develops AI-driven longevity therapeutics, including first-in-class Anti-Necrotic necrosis inhibitors for kidney disease and other applications. | 8 | 2 | – | Babraham Research Campus, Cambridge, UK |
| Loyal Loyal develops longevity drugs for dogs that target age-associated disease and disability. | 7 | 3 | series c plus | SAN FRANCISCO |
| MetroBiotech MetroBiotech develops proprietary NAD+ precursors to enhance human healthspan and treat age-related diseases. | 6 | 3 | – | – |
| Mirscience Therapeutics Mirscience Therapeutics develops personalized microRNA therapies for longevity-associated diseases and challenging therapeutic targets. | 7 | 1 | – | Brazil |
| Mitochem Therapeutics MitoChem Therapeutics develops small molecules targeting mitochondrial dysfunction-driven loss of cellular metabolism in neurodegenerative disease. | 7 | 2 | – | Charleston, South Carolina, United States |
| Mitoconix Bio Mitoconix Bio develops disease-modifying therapeutics for neurodegenerative diseases by improving mitochondrial health. | 8 | 1 | – | Israel |
| Mitotech Mitotech develops orally bioavailable small molecules to protect mitochondria from oxidative stress and enhance energy expenditure. | 6 | 4 | – | Russia, Luxembourg |
| Mogling Bio Mogling Bio develops pharmacological therapies targeting Cdc42 overactivation to rejuvenate aged and exhausted cells, especially stem cells. | 8 | 3 | seed | 2900 Reading Road Suite #410 Cincinnati OH 45206 |
| Muna Therapeutics Muna Therapeutics develops therapies to slow or stop neurodegenerative diseases including Alzheimer’s and Parkinson’s. | 8 | 3 | – | Copenhagen, Denmark |
| Napa Therapeutics Napa Therapeutics develops small molecule drugs against a novel aging-related target linked to NAD metabolism. | 7 | 1 | – | San Francisco, California, United States |
| NeuroBio Neuro-Bio develops diagnostic and therapeutic strategies for Alzheimer's disease based on the toxic T14 peptide mechanism. | 8 | 2 | seed | Oxford, United Kingdom |
| NRG Therapeutics NRG Therapeutics develops disease-modifying medicines for neurodegenerative disorders by targeting mitochondrial function. | 8 | 2 | – | Stevenage, Hertfordshire United Kingdom |
| NuSirt NuSirt Sciences combines established pharmaceuticals and natural products to activate the sirtuin pathway for cardiometabolic diseases of aging and overnutrition. | 5 | 3 | – | Knoxville, Tennessee, United States |
| Olatec Olatec develops safe oral NLRP3 antagonist therapeutics for acute and chronic inflammatory diseases. | 7 | 5 | – | New York City, New York, United States; Boston, Massachusetts, United States |
| Pelage Pharmaceuticals Pelage develops regenerative medicines for hair loss grounded in stem cell biology. | 6 | 3 | series b | Los Angeles, California, United States |
| PharmatrophiX PharmatrophiX develops small-molecule disease-modifying therapies for neurodegenerative diseases. | 8 | 4 | – | San Francisco, California, United States |
| Praetego | 7 | 2 | – | Durham, North Carolina, United States |
| Pretzel Therapeutics Pretzel develops first-in-class medicines targeting mitochondrial biology and cellular energetics for rare, neurodegenerative, metabolic, and other diseases. | 8 | 4 | series a | Sweden; Boston, Massachusetts, United States |
| Refoxy Pharma Refoxy develops next-generation medicines targeting FOXO3 to treat age-related diseases and extend healthy lifespan. | 7 | 2 | – | Germany |
| ReGENE ReGENE develops small molecule therapies to prevent and treat aging-associated diseases by targeting mechanisms that drive aging. | 7 | 1 | – | Springfield, Massachusetts, United States |
| resTORbio Clinical-stage biopharmaceutical company developing medicines targeting the biology of aging to prevent or treat aging-related diseases. | 7 | 2 | – | Boston, Massachusetts, United States |
| Retrotope Retrotope develops proprietary therapeutics designed to treat degenerative disease by down-regulating lipid peroxidation. | 7 | 4 | series c plus | San Francisco, California, United States |
| Scripta Therapeutics Scripta Therapeutics modulates transcription factor activity using AI/ML-driven drug discovery to develop disease-modifying therapeutics. | 8 | 0 | – | Oxford, United Kingdom |
| Senisca Senisca develops RNA senotherapeutics to reverse cellular senescence and treat age-related disease. | 8 | 1 | seed | Exeter, United Kingdom |
| Sentcell Sentcell develops first-in-class human rejuvenating therapies targeting the sMAC pathway in ageing T cells. | 9 | 2 | series a | London, United Kingdom |
| Ship of Theseus A therapeutics company developing degradation-resistant Hox family biologics. | 7 | 4 | – | Philadelphia, Pennsylvania, United States |
| Sierra Sciences Sierra Sciences researches telomere science and telomerase activation to develop interventions intended to reverse cellular aging. | 8 | 0 | – | Reno, Nevada, United States |
| TNF Pharmaceuticals (was MyMD) Clinical-stage biopharma developing MYMD-1 and Supera-CBD for autoimmune, inflammatory, aging-related, pain, anxiety and seizure indications. | 6 | 2 | public | Baltimore, Maryland, United States |
| TOR Therapeutics TOR Therapeutics develops an oral fixed-dose combination of mTORC1 inhibitors for Alzheimer's disease and other mTORC1-driven disorders. | 7 | 0 | – | Jenkintown, Pennsylvania, United States |
| Tornado Therapeutics Tornado Therapeutics is developing safer, more effective rapalogs to treat disease and extend healthy lifespan. | 8 | 0 | – | United States |
| Trivium Vet TriviumVet develops animal health therapeutics for serious diseases in cats and dogs. | 6 | 4 | acquired | Ireland |
| Vasa Therapeutics Vasa develops therapeutics targeting cardiovascular aging, neuromuscular disease, and age-related disorders. | 7 | 2 | seed | Encinitas, California, United States |
| X-tosis X-tosis develops mitochondrial therapeutics to prevent neuronal loss in neurodegenerative diseases. | 8 | 2 | – | Gainesville, Florida, United States |
| YOXLO YOXLO builds science-based tools, products and research programs to help people understand and preserve functional reserve as they age. | 7 | 2 | pre seed | YOXLO B.V. Biopartner 5 Building De Limes 7 2343 DH Oegstgeest |
| Zoe Biosciences Zoe Biosciences is developing best-in-class therapies to treat cardiometabolic disease. | 6 | 0 | – | United States |
Проекты
Проекты этого направления
| Проект▲ | Стадия▲ | Самый веский аргумент против▲ |
|---|---|---|
| A NEW DIMENSION A NEW DIMENSION appears to be Aayam Therapeutics’ mitochondria-focused longevity effort: a drug-discovery and development project built around an undisclosed "LADR 4" platform and framed as delivering affordable, accessible therapeutics. | Early but real. | The project may fail because its public evidence is currently far weaker than its positioning: the mechanism is opaque, the platform is undefined, and mitochondria is a crowded, hype-prone area where patenting, competition recognition, and expert biography do not by themselves predict clinical efficacy. |
| Alpha Rejuvenation Alpha Rejuvenation appears to be a California-focused men’s health and wellness clinic marketing peptide therapies, testosterone replacement, erectile-dysfunction treatment, pelvic-floor therapy, NAD+, and semaglutide-based weight loss rather than a clearly documented R&D program. | Operational as a men’s rejuvenation clinic with named services, office details, and a stated licensing footprint limited to California and Arizona. | This may be mostly a marketing-driven men’s wellness clinic aggregating loosely supported interventions, with weak causal evidence, heavy reliance on testimonials and educational copy, unclear differentiation from standard cash-pay hormone/weight-loss practice, and a material evidence-quality problem around source attribution. |
| Aptah Bio Aptah Bio is a U.S.-based startup developing RNA therapeutics, centered on a U1 snRNP-modulating platform it calls RNA WiCo/RNA rejuvenation, for neurodegeneration, cancer, and other age-related diseases. | Preclinical. | The failure case is that Aptah’s claimed breadth is mostly narrative, while the real effects are narrow, model-specific, or too small to translate. |
| Beijing Joekai Biotechnology Beijing Joekai Biotechnology appears to be a Beijing-based small-molecule neurodegeneration company centered on Alzheimer’s disease. | Historically, Joekai held Alzheimer’s-treatment patent filings and grants tied to synthetic compounds, though several records show ceased or fee-related expiry risks. | The evidence base is still dominated by patents, directory entries, and conference/trial metadata without published outcomes, so the project could easily be a case where a plausible mechanism and real clinical activity never translate into meaningful efficacy, differentiation, or durable IP advantage. |
| Beiwe Beiwe appears to be an early therapeutic project centered on selective mTORC1 inhibition for longevity and cancer, with the core claim that it can preserve rapamycin-like benefits while avoiding mTORC2-related toxicity; however, the evidence here is mostly undated self-published website copy with no linked primary datasets, study details, patent record tied to the company, or disclosed clinical results. | Publicly presented as a company with a therapeutic thesis and named team members including Gino Cortopassi, PhD, and Zane Starkewolfe, PhD, but the supplied evidence does not show Beiwe-specific preclinical datasets, peer-reviewed papers, patents assigned to the project, trial registrations, or clinical-stage progress. | The current evidence does not substantiate the key claims. |
| BioArmor BioArmor appears to be an early-stage, student-led longevity concept from the QuestX Incubator in Kuala Lumpur that reached XPRIZE Healthspan semifinalist status, but the public evidence does not disclose a validated therapeutic program. | Status is best described as concept-stage with publicity and competition recognition but little disclosed validation. | The downside case is stronger on current evidence: BioArmor may be mostly a narrative bundle of popular longevity ingredients plus futuristic claims that are far ahead of any disclosed proof. |
| Cura Therapeutics and collaborators/ Cura Therapeutics appears to be a small, women-led biotech developing multifunctional fusion-protein therapeutics for metastatic cancer and age-related diseases, with recurring claims around multimodal immune activation plus anti-fibrotic and anti-senescence effects. | Status is best described as early translational with inconsistent but convergent signals of advancement. | The project may fail because most of the current support is still promotional, patent-based, or inherited from older academic fusokine work rather than direct proof that Cura's own candidates are effective, manufacturable, and safe in humans. |
| Klotho Longevity Klotho Longevity is a U.S. commercialization effort centered on Klotho-linked anti-aging products and procedures, led by Dr. | Current status appears to be an operating U.S. clinic-and-brand ecosystem with active commercialization, promotional conference visibility, and at least one granted Klotho-production patent linked to Gail Humble. | The downside case is that this is mostly a branding-and-patent story built on a biologically interesting target without adequate proof that project-specific products deliver meaningful human longevity benefits. |
| Lono Jaeyak Lono Jaeyak appears to be an anti-senescence composition program known only from a pending European patent application claiming formulations for rejuvenating senescent cells or delaying/preventing cellular aging. | Status is early and weakly validated. | The downside case is that this is only a broad patent filing with little evidentiary substance behind it. |
| Nishimura Lab Nishimura Lab appears, on the evidence provided, to be an EADERM-linked regenerative dermatology effort built around hair follicle and epidermal stem-cell biology, especially aging- and injury-related mechanisms involving COL17A1 and stem-cell motility. | Preclinical and early commercial. | This project could fail because the current evidence is still mostly a chain of academic titles, patents, and company positioning rather than hard translational proof. |
| NYC-Vita NYC-Vita is a Mount Sinai-led, New York City pilot longevity trial that appears to combine home-based exercise, daily spermidine, and low-dose rapamycin or lamivudine in adults roughly 65-80, with the stated goal of improving immune function, muscle strength, cognition, and overall healthspan. | Status is early and unproven. | NYC-Vita could fail because the intervention is a heterogeneous bundle with weak attribution, small sample size, and substantial forward-looking promotional framing; the most likely disappointing outcome is that exercise explains most of the effect, while rapamycin/lamivudine add safety risk, noise, or negligible incremental benefit without clear mechanistic readouts. |
| RIGHT Trial RIGHT Trial appears to be a University of Pittsburgh-led Phase 2, 24-week, placebo-controlled trial testing subcutaneous clazakizumab, an IL-6 blocker, in older adults with frailty and mobility limitation. | Clinical-stage and actively structured as a mid-stage efficacy/safety test, with University of Pittsburgh as lead sponsor, Anne B. | Frailty is biologically heterogeneous and may not respond meaningfully to single-cytokine suppression; even if IL-6 is associated with frailty, blocking it may produce limited functional benefit, unacceptable tradeoffs, or effects too small to justify chronic biologic treatment in older adults. |
| Team GlyNAC Team GlyNAC appears to be a Baylor College of Medicine-associated translational longevity project built around GlyNAC, a glycine plus N-acetylcysteine supplementation strategy intended to raise glutathione and improve mitochondrial and oxidative-stress-related aging defects. | Status is early clinical and preclinical, not validated. | The main failure case is that the project is over-extrapolating from small studies, institutional news coverage, and mouse data: biomarker improvements may not translate into durable clinical benefit, lifespan effects may be species-specific, sex-dependent responses may complicate generalization, and Baylor’s patent/licensing position creates conflict-of-interest pressure around interpretation. |
| Team Twilight Team Twilight is a U.S. biotech startup developing active immunotherapies against pathological proteins, especially HERV-K-linked targets in ALS, with broader stated ambitions in Alzheimer’s, Parkinson’s, and chronic pain. | The project appears to be a venture-stage therapeutic company in a preclinical or at least not yet clinically validated state based on the evidence here. | The main failure case is that the project is still resting on promotional claims plus field-context biology that does not yet prove intervention efficacy. |
| The Brigham Boston XPrize The Brigham-Boston XPRIZE Healthspan Team is a Mass General Brigham and Harvard-linked effort that became a Top 40 semifinalist in the seven-year, $101M XPRIZE Healthspan competition and received $250,000 in Milestone 1 funding in 2025. | As of May 12, 2025, the team was named a Top 40 semifinalist in XPRIZE Healthspan and awarded $250,000 in Milestone 1 funding. | The main failure mode is that the project remains high-profile but underspecified: the therapeutic is unnamed, the evidence is currently promotional rather than experimental, and the pilot may fail to produce endpoints or biomarkers that are persuasive enough to support a larger trial or any real conclusion about healthspan benefit. |
| TIME TRAVELER AND NUREKI TIME TRAVELER AND NUREKI presents as a University of Tokyo-linked startup pursuing healthy-aging products and therapeutics, especially plant-cell-derived exosomes and molecules said to inhibit aging-linked genes, with stated interests in cancer, frailty/sarcopenia, cachexia, supplements, and cosmetics. | Early-stage startup. | The main failure case is that the project is currently much stronger in narrative, patent-adjacent field context, and product marketing than in demonstrated science. |
| YOXLO YOXLO is a Dutch longevity startup building a proprietary healthspan intervention, Youniqor, around a centenarian-inspired thesis that mitochondrial function, cellular resilience, and inflammatory control, especially NLRP3-linked immune signaling, can be modulated to preserve strength, cognition, independence, and immune function with age. | YOXLO has a named founder and cofounding team, a live company website in 2025, SAFE fundraising, and XPRIZE Healthspan semifinalist recognition. | The strongest failure case is that YOXLO is currently much stronger on narrative, patents, and competition signaling than on disclosed evidence, and that its broad claims about mitochondria, oxidative stress, immune balance, and NLRP3 will not survive rigorous testing because the formulation effect size is small, nonspecific, or not mechanistically tied to the promised healthspan outcomes. |
Люди
Люди этого направления
- Aubrey de Greypopulariser · через Sierra Sciences
SENS Foundation founder and longevity advocacy pioneer.
- Alex Zhavoronkovpopulariser · через Napa Therapeutics
- João Pedro de Magalhãesscientist · через 5 Alarm Bio
Senescence.info founder and aging-database builder.
- Matt Kaeberleinscientist · через Hayflick Partners
- Laura Deminginvestor · через Loyal
Founded The Longevity Fund as an early dedicated VC vehicle for aging and life-extension companies, helping make longevity biotech a fundable startup category.
- Eric Verdinscientist · через BHB Therapeutics
- Celine Haliouaentrepreneur · через Loyal
Biotech founder pursuing the first approved lifespan-extension drugs for dogs
- Nir Barzilaiscientist · через SirtLab Corp
- Daisy Robintonentrepreneur · через Tornado Therapeutics
Biotech founder developing therapeutics for ovarian aging and women’s health
- Kristen Fortneyentrepreneur · через BioAge Labs
- Jim Mellonentrepreneur · через Napa Therapeutics
Co-founded Juvenescence and publicly framed longevity as an investable biotechnology thesis through the book Juvenescence and substantial company-building activity.
- James Peyerentrepreneur · через Amplifier Therapeutics
Biotech builder translating aging biology into a portfolio of medicines
- David Sinclairscientist · через MetroBiotech
- Joe Betts-LaCroixentrepreneur · через BioAge Labs
Biotech entrepreneur building therapies for age-driven disease
- Christian Angermayerentrepreneur · через Cambrian Bio
- Kelsey Moodyentrepreneur · через Ship of Theseus
Drug-development entrepreneur building an integrated longevity biotech platform
- Peter Diamandisentrepreneur · через Immunis
Хронология
События и даты
- Грант
X-tosis
The Michael J. Fox Foundation
- Заёмное финансирование
Biophytis
Hexagon Capital Fund
- Дополнительное размещение акций
HCW Biologics
$4M
- Дополнительное размещение акций
Jupiter Neurosciences
$2M
- Дополнительное размещение акций
Biophytis
- Грант
Cambrian Bio
$30.8M · ARPA-H PROSPR program
- Раунд C
Loyal
$100M · Age1
- Грант
Muna Therapeutics
$1M · Alzheimer's Association
- Раунд B
Aeovian Pharmaceuticals
$55M · Luma Group, CTI Life Sciences Fund
- Посевной раунд
Scripta Therapeutics
$12M
- Раунд B
Pelage Pharmaceuticals
$120M · ARCH Venture Partners, GV
- Грант
ADvantage Therapeutics
$2.5M · NIH SBIR
- Раунд B
NRG Therapeutics
$67M · SV Health Investors’ Dementia Discovery Fund
- Грант
Ship of Theseus
- Раунд A
Jocasta Neuroscience
$35M
- Инвестиционный раунд
ADvantage Therapeutics
$3.5M
- Инвестиционный раунд
Pretzel Therapeutics
- Инвестиционный раунд
Etheros Pharmaceuticals
$600K
- Раунд B
Juvenescence
$76M · M42
- Покупка компании
Trivium Vet
PBI-Gordon Companies
- Посевной раунд
Refoxy Pharma
$9.8M · Boehringer Ingelheim Venture Fund (BIVF)
- Инвестиционный раунд
Aeovian Pharmaceuticals
$50M · Hevolution Foundation
- Раунд B
Loyal
$45M · Bain Capital Ventures
- Заёмное финансирование
Loyal
$12.5M · Bridge Bank
Гипотезы
Проверяемые гипотезы по этому направлению
Гипотезы опубликованы системой Omega Point и отнесены к этому направлению классификатором; под каждой указан пробел в знаниях, который она призвана восполнить
- Рецепторы липидов в коже могут запускать передачу сигналов внутри организма и тем самым уменьшать повреждение отдалённых тканей10 окт. 2026 г.В модели с парными эксплантатами кожи пожилых людей, связанными с эндотелиальными клетками человека, нанесённый на кожу липид может вызывать выработку в коже медиатора, уменьшающего повреждение отдалённых клеток. Избирательная блокада медиатора должна устранять его защитный эффект, а повторное добавление должно восстанавливать этот эффект. Если в достаточно тщательно проверенных условиях этого не происходит, такой результат поставит предложенный механизм под сомнение.
- Тренировки могут повысить почечную фильтрацию и затраты кислорода на транспорт натрия до уровня, вызывающего дефицит кислорода10 окт. 2026 г.В подгруппе пожилых людей, характеристики которой изучены проспективно, продолжение тренировок может улучшать подвижность и одновременно повышать почечную фильтрацию, увеличивать затраты на транспорт натрия и приводить к стойкому ухудшению состояния почек при обычной физической активности в тёплых условиях. Если с достаточной точностью установлено, что реакция в ходе тренировок не формируется, избыточное потребление кислорода не возникает, кислородный дисбаланс отсутствует или стойкое нарушение функции почек не развивается, это опровергнет соответствующее звено гипотезы.
- Блокада интерлейкина-11 может смещать репарацию генома в сторону соединения концов с повышенной частотой ошибок10 окт. 2026 г.В заранее определённой популяции делящихся эпителиальных клеток-предшественников, полученных от стареющих людей, блокада интерлейкина-11 может увеличивать число структурных ошибок репарации, несмотря на уменьшение воспалительного повреждения и сохранение функции на раннем этапе. Если бы при сопоставимых исходных повреждениях подтвердилась эквивалентность точности репарации в заданных пределах, это ограничило бы применимость этой гипотезы.
- Блокада интерлейкина-11 может изменить состав собственных пептидов на поверхности клеток и вызвать иммунное повреждение10 окт. 2026 г.При наличии предрасположенности блокада интерлейкина-11 может изменить расщепление белков и состав собственных пептидов, представленных на поверхности клеток эпителиальных тканей стареющего человека. В результате уже существующие T-клетки памяти могут вызывать длительное повреждение. Повреждение, возникающее независимо от распознавания указанного пептида T-клетками, свидетельствовало бы против предложенного механизма.
- Блокада интерлейкина-11 может поддерживать вредные конкурирующие сигналы за счёт высвобождения общего компонента рецепторов10 окт. 2026 г.В эпителиальных клетках пожилых людей блокада интерлейкина-11 может высвобождать общий компонент рецепторов gp130, делая его доступным для конкурирующих рецепторов и тем самым поддерживая вредные последствия. Чтобы проверить этот механизм, необходимо выяснить, происходит ли обмен компонентами внутри лимитирующего поверхностного пула и сохраняются ли нарушения функций. Нейтральное, полезное или временное перераспределение не подтвердит этот механизм вредного воздействия.
- Связность митохондрий может защищать стареющие клетки сердца при снижении поступления глутамина из мышц6 окт. 2026 г.Миметик раннего голодания может защищать стареющие клетки сердечной мышцы, сохраняя связность их митохондрий и снижая зависимость от глутамина из мышц. Гипотеза будет отвергнута, если независимые изменения связности не сдвинут порог, при котором сердце теряет функцию при снижении активности глутаминазы.
- Мышечный глутамин может защищать сердце, поддерживая обезвреживание перекисей липидов с участием глутатиона6 окт. 2026 г.Миметик раннего голодания может защищать сердце за счёт использования мышечного глутамина для синтеза глутатиона. Эту гипотезу поставил бы под сомнение любой из двух результатов. В первом случае защита возвращается, если восстановить только энергоснабжение. Во втором случае функция не восстанавливается, хотя повреждение липидов блокировано, а окисление глутамина остаётся сниженным.
- Мышечный глутамин может защищать сердце, поставляя азот для гликозилирования белков6 окт. 2026 г.Если приём пищи откладывается, мышечный глутамин может поддерживать качество белков сердца, поставляя азот для синтеза сахаров. Согласно гипотезе, блокада этого пути устраняет защитный эффект, даже если энергетическое обеспечение и уровень глутатиона сохраняются. Если при такой блокаде защита сохраняется, это опровергнет утверждение о необходимости этого пути для защитного эффекта.
- Миметики раннего голодания могут защищать сердце за счёт окисления глутамина, поступающего из мышц6 окт. 2026 г.У старых мышей при задержке кормления миметик голодания может поддерживать энергетическое обеспечение сердца за счёт глутамина из мышц, что при повторных циклах может приводить к потере мышечной массы. Если в изолированном сердце альтернативное топливо не вернёт защитный эффект, хотя восстановление энергетического потока будет подтверждено, этот результат опровергнет гипотезу.
- При несогласованной сборке рибосом восстановление мышц может ограничивать продление жизни миметиками голодания6 окт. 2026 г.У старых мышей синтез белка в мышцах между циклами применения миметика голодания может опережать сборку рибосом. Это может приводить к токсичному накоплению белков и ограничивать продление жизни. Если бы между циклами препятствовали восстановлению синтеза белка в мышцах и это сокращало бы жизнь при нормальной сборке рибосом, это свидетельствовало бы против гипотезы.
- Неполное восстановление саркомеров может лишить миметик голодания способности продлевать жизнь6 окт. 2026 г.Блокирование восстановления мышц между циклами может лишить миметик голодания способности продлевать жизнь, поскольку препятствует замене филамина C в Z-дисках. Утрата этого эффекта при сохранных Z-дисках и отсутствии зависимости от механической нагрузки опровергла бы предполагаемый механизм.
- Подавление смертельных заболеваний вне мышц может сохранить способность миметика продлевать жизнь6 окт. 2026 г.Вещество, имитирующее эффекты голодания, может продлевать жизнь животных за счёт подавления смертельных заболеваний в тканях вне мышц, даже при блокировании восстановления мышц. Гипотеза опровергается, если восстановление мышц возобновляется и благодаря этому возвращается утраченный положительный эффект на выживаемость, а патология в остальных тканях остаётся сопоставимой.
Прогнозы
Прогнозы по этому направлению
- When will the first NEDD8-pathway drug with a longevity indication reach Phase 2b trials?17% за «да»к 1 нояб. 2026 г.
- When will a Phase 2/3 trial show an aging-biology target improving a hard functional endpoint beyond molecular markers?17% за «да»к 1 нояб. 2026 г.
- When will therapeutic plasmapheresis confirm a reduction in biological age or mortality in a randomized trial?17% за «да»к 1 нояб. 2026 г.
- In what year will Loyal get FDA conditional approval for a daily dog-longevity pill?17% за «да»к 1 нояб. 2026 г.
- Will canagliflozin (SGLT2 inhibitor) plus low-dose rapamycin show synergy in old marmosets — HSC rejuvenation without high-dose immunosuppression?17% за «да»к 1 нояб. 2026 г.
- Will TRIAD (rapamycin in aging dogs, 580 animals, 3-year design) show a survival or disease-onset benefit by 30 Jun 2028?20% за «да»к 1 нояб. 2026 г.
- Will a large rapamycin/rapalog trial in older adults show a convincing signal on immune resilience, frailty, or functional endpoints before 2028?20% за «да»к 1 нояб. 2026 г.
- Will Retro Biosciences publish first human safety/PK/biomarker data on RTR242 and move to Phase 2 by 30 Jun 2028?20% за «да»к 1 нояб. 2026 г.
В этом месяце
Последние сообщения
- In mice, an age-related decline in selective protein breakdown impairs macrophage clearance of senescent cells, while the compound CA77.1 activates this process and limited their accumulation20 окт. 2026 г.Age-related loss of CMA weakens macrophage clearance of senescent cells in mice, while CA77.1 restores clearance and reduces senescent-cell accumulation and lung fibrosis.
- Delivering the gene for METTL14, a protein that works with a partner to add chemical marks to RNA, to heart cells reduced scarring in mice with progeria, a disease of accelerated aging, and extended lifespan in one of two mouse lines20 окт. 2026 г.Heart-targeted METTL14 gene delivery reduced cardiac fibrosis in two mouse models of progeria and extended lifespan in one model.
- MIT Technology Review reporter supports drugs to extend pets’ lives and rejects $50 000 cloning and storage of dead animals in liquid nitrogen20 окт. 2026 г.A reporter supports lifespan-extending drugs for pets but rejects cloning and cryonics, arguing that individual animals cannot be replaced or revived.
- Scientists have extended life in worms and mice, but have yet to do so in humans, former BMJ editor writes; aging researcher de Magalhães accepts criticism of the hype and remains confident that human aging can be slowed20 окт. 2026 г.Longevity advocates concede that animal lifespan gains have not translated to humans but argue that better trials could show whether aging can be slowed.
- Cellino launches Reservoir: for $4995, adults can have blood collected at home and their immune cells frozen and stored in their name for the first year20 окт. 2026 г.Cellino’s Reservoir service collects and cryopreserves immune cells for possible future therapies, though their long-term clinical value remains unproven.
- Preprint: activating the bile acid receptor TGR5 increased the number of dividing hippocampal stem cells and improved novel-arm discrimination in aged mice19 окт. 2026 г.TGR5 activation increased dividing hippocampal stem cells and improved novel-arm discrimination in aged mice, with effects lost after local TGR5 suppression.
- A gel carrying the gene for the enzyme TKT accelerated wound healing in diabetic mice and pigs19 окт. 2026 г.A TKT gene-delivering hydrogel restored blood vessel formation and accelerated diabetic wound healing in mice and pigs.
- Protein patch for knee cartilage repair tested in 17 patients17 окт. 2026 г.A cell-free protein patch made from pig cartilage scaffolds improved pain and knee function in 17 patients, with repair tissue increasingly resembling hyaline cartilage.